Available 24/7 (877) 245-6707

Injured by Gadolinium?

If you or a loved one have had an MRI with contrast agent and experience one or more of the following side effects, contact our Gadolinum Injury Attorneys today to find out if you have a case!

  • Brain fog
  • Skin irritations, such as discoloration, thickening, or itching
  • Bone and joint pains
  • Violent shaking
  • Burning sensations
  • Cognitive deficits
  • Kidney damage

About Gadolinium Injuries

TRUTH: Gadolinium in its naturally-occurring form is toxic to the human body.

TRUTH: The FDA has called for further research involving the safety and toxic buildup of
gadolinium-based contrast agents.

TRUTH: The FDA has required improved warning labels and information to be shared with
patients when considering the use of gadolinium-based contrast agents.

The case against gadolinium is escalating. If you’re experiencing signs of gadolinium toxicity, seek medical
help and legal representation. Don’t go it alone.

Contact our highly-qualified legal team today  for help determine the next steps for
your gadolinium case.


Each year 11% of people in the USA receive an MRI (magnetic resonance imaging) or MRA (magnetic resonance
angiography). Out of those, 30-50% are asked to use a contrast agent to help provide a better picture of their
health. One in three contrast agents include gadolinium as an ingredient. As you can see, usage of gadolinium
is widespread.

Lawsuits involving gadolinium have occurred for nearly a decade, but recent news or radio segments are
starting to pop up about its dangers. The public has a right to understand what they’re taking and what the
risks are in contrast agents, various imaging tests, and ingredients such as gadolinium.

What Is Gadolinium?

Gadolinium is a heavy and rare earth metal that responds to magnetic energy. Its ability to absorb neutrons
and the paramagnetic property has enabled the element to be used in a variety of applications.

Primarily, it is used by radiologists as a chemical contrast agent. There are two types of contrast agents
based on their chemical composition, linear and macrocyclic. Gadolinium is found in linear contrast agents.

Gadolinium contrast agents are often used to help target tumors in neutron therapy by providing a more
accurate picture of a patient’s health. There are non-medical uses as well. In metal or salt form, gadolinium
is occasionally used in nuclear facilities for shielding or emergency shutdown measures.

Why Do Radiologists Use Gadolinium-Based Agents?

In its liquid form used as a contrast agent, gadolinium-based contrast agent (or GBCA) is injected into
patients before receiving an MRI or MRA. This agent, when administered into the human body, magnifies the
presence of abnormalities or disease due to the reaction gadolinium has with the magnetic field during the
scan. For this reason, radiologists may consider gadolinium to provide a more enhanced view in the resulting

What Is Gadolinium Made Of? Is It Toxic?

Gadolinium itself is a rare, but naturally-occurring element that is toxic to humans in its natural state. The
gadolinium-based contrast agent (GBCA) used by radiologists is made of the gadolinium ion and a chelating
agent, or carrier model, which is used to counteract the toxicity of gadolinium yet still maintain its
contrasting properties for MRI and MRA scans.

Who Makes GBCA?

Gadolinium-based contrast agents are manufactured by a number of companies, with each brand using a different
chelating molecule. Companies that produce gadolinium-based contrast agents and their brand names can be found
in the list below.

● Magnevist (Bayer-Schering) – Linear Ionic
● MultiHance (Bracco Diagnostics) – Linear Ionic
● ProHance (Bracco Diagnostics) – Macrocyclic Non-Ionic
● Omniscan (GE Healthcare) – Linear Non-ionic
● Dotarem (Guerbet) – Macrocyclic Ionic
● Gadavist (Bayer) – Macrocyclic Non-ionic
● Evoist or Primovist (Bayer) – Linear Ionic

Dangers of Gadolinium

Although it may be confusing, gadolinium is not specifically radioactive. Gadolinium in its natural state is
toxic to humans, so there are other illness risks requiring further research to determine the long-term effects
of gadolinium accumulation in the human body.

Gadolinium & The Human Body

Unlike lead or other metals that can enter the human body in small amounts during day-to-day activities,
gadolinium only enters the body through the use of a contrast agent for MRI’s and MRA’s.

However, as with any foreign metal that enters the human body, a buildup can occur. When heavy metals such as
gadolinium get backed up within the body, it can become toxic or even deadly. This is caused by foreign metal
preventing normal functions in the organs, leading to health complications and potentially serious medical
conditions, such as nephrogenic systemic fibrosis (NSF).

When this buildup occurs, many refer to it as gadolinium toxicity.

Does Impaired Kidney Function Cause Risk for Gadolinium Toxicity?

About 10 years ago, it was revealed that patients with impaired kidney function who received gadolinium
experienced further health complications. One of the more common conditions was identified as nephrogenic
systemic fibrosis (NSF). NSF is a disease that affects the internal organs and the skin, causing deposits and
thickening or hardening in a variety of locations, which can become both uncomfortable and dangerous for

The initial assumption was that these patients’ medical conditions made their bodies unable to effectively
remove gadolinium. This resulted in the build-up of gadolinium to where it became toxic, causing the
development of NSF.

We now know this isn’t true. In 2017, the FDA declared, “There is no direct correlation with healthy kidneys
and developing NSF because of gadolinium,” but that further research on the risks of gadolinium build-up and
its effects continue to be studied.

As of 2018, multiple cases have surfaced where patients with healthy kidneys developed NSF or are experiencing
health-related complications believed to be associated with gadolinium toxicity. This is what has caused the
spike in lawsuits, news coverage, and questions regarding its safety.

What Are Potential Side Effects or Disease from Gadolinium?

If you or a loved one underwent an MRI or MRA scan and received a gadolinium-based contrast agent, the
following are potential side effects:

● Brain fog

● Skin irritations, such as discoloration, thickening, or itching

● Bone and joint pains

● Violent shaking

● Burning sensations

● Cognitive deficits

● Kidney damage

Some diseases that can develop from gadolinium toxicity include:

● Nephrogenic Systemic Fibrosis (NSF)

● Nephrogenic Fibrosing Dermopathy (NFD)

● Gadolinium Deposition or Toxicity Disease

Who Has the Highest Risk for Complications Involving Gadolinium?

In 2017, the FDA confirmed that the following patients would be most at risk of experiencing complications
directly related to gadolinium toxicity and should not receive contrast agents that include the element:

● Expecting mothers or women who may be pregnant

● Children or the elderly

● Patients with dysfunction or severe kidney problems

● Patients who have already received multiple MRI scans that included injection of gadolinium-based contrast

Warning Signs of Gadolinium Toxicity

In a 2014 survey looking into the chronic effects of retained gadolinium from contrast MRIs, some of the
warning signs of gadolinium toxicity were identified as:

● Pain – aching; burning, tingling, and/or prickling pain (paresthesia); deep bone pain.  Typically in
extremities or joints, and sometimes in the location where the MRI occurred, like the head.

● Dermal changes – like tight skin, lesions, hyperpigmentation; most often in extremities.

● Muscle issues – twitching; small, local, rapid contractions and weakness.

● Ocular problems – worsening vision,  dry eyes, bloodshot eyes.

● Cognitive symptoms

● Ear, nose and throat issues – tinnitus, swallowing, and voice problems

● Low body temperature

● Hair loss

● Itchy skin

● Balance problems

● Edema – swelling of extremities

What Are “Brain Deposits?” Are They Dangerous?

Gadolinium “brain deposits” are the accumulation of gadolinium in the human brain, specifically in the globus
pallidus and dentate nuclei. Currently, only the injection of gadolinium-based contrast agents into the human
body during MRI and MRA procedures introduces gadolinium that is absorbed into the human body. It generally
requires multiple injections or scans for the build-up to take place.

In a 2017 study completed by the International Society for Magnetic Resonance in Medicine and tracked in the National Institutes of
, researchers found that the “extent of gadolinium deposition in the brain varies based on the
agent” and that “the clinical significance of retained gadolinium in the human brain remains unknown, with data
currently available for humans or animals showing the adverse effects gadolinium deposition has on the brain.”

It’s clear that more research is needed for gadolinium toxicity and potential patient risks to be fully

Why Hasn’t the FDA Recalled/Banned Gadolinium?

The current stance of the FDA on gadolinium-based contrast agents is that the benefit of the approved agent
outweighs the cost. In a public statement in 2017, the FDA declared “Gadolinium retention has not been directly linked to adverse health conditions in
patients with normal kidney function,” but that “manufacturers of GBCA products are required to conduct further human and animal studies to better assess
the safety of these contrast agents.”

A brief history of the FDA’s investigations into gadolinium-based contrast agents and their manufacturers

● In 2010, the FDA first became aware of the risks associated with gadolinium when gadolinium-based contrast
agents were linked
to causing nephrogenic systemic fibrosis
 (NSF) in patients with dysfunction kidneys.

● Lawsuits leading to pressure from the FDA required accurate GBCA labeling and warning to be given to
patients about the risks associated with the agent.

● In 2015, the FDA started looking into the risk of brain deposits due to repeated usage of gadolinium-based
contrast agents in patients.

● In early 2017, the FDA publicly declared that “initial investigative research revealed no harmful effects of
gadolinium build-up in the brain,” but that further review was needed.

● In late 2017, the FDA called for further warnings and safety measures to be put in place regarding GBCA’s,
along with new
class warnings

● In 2018, the FDA supplied an additional update that the organization approved a new patient medication guides. To search the FDA’s patient medication
guides database, click

I’m a Victim of Gadolinium Toxicity. What Happens Next?

Investigations into gadolinium-based contrast agents have revealed a high probability that manufacturers and
researchers have been aware of the risks associated with gadolinium in contrast agents, most likely since its
introduction and approval by the FDA in the 1980’s.

You may be able to receive compensation if you fit some of the following criteria:

● Undergone multiple MRI’s with GBCAs

● Received multiple gadolinium-based contrast agent injections

● Been diagnosed with or showing symptoms of Gadolinium Deposition Disease, otherwise known as gadolinium

● Been diagnosed with or showing symptoms of Nephrogenic Systemic Fibrosis (NSF)  or Nephrogenic Fibrosing
Dermopathy (NFD)

Victims may be able to join a class action lawsuit or have one filed on their behalf to receive compensation.
Speak with one of our attorneys experienced in medical lawsuits to help determine if you have a case and what
your next steps should be.